- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01139177
SAMBA EU Femoropopliteal Trial
7. juni 2010 opdateret af: NovoStent Corporation
The primary objective of this study is to evaluate the safety and performance of the SAMBA Stent and Delivery System in the treatment of femoropopliteal lesions.
Studieoversigt
Status
Ukendt
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
39
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Bad Krozingen, Tyskland, D 79189
- Herz Zentrum Bad Krozingen
-
Leipzig, Tyskland, D-04289
- Herz-Zentrum Leipzig
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
21 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
Screening
- Patient must be ≥ 21 years of age with life expectancy > 1 year.
- Symptomatic leg ischemia requiring treatment of the superficial femoral and/or popliteal artery (Rutherford category 2-4; claudication, rest pain).
- Patient must be a suitable candidate for PTA and stenting.
- Patient is willing and able to return to the site of the investigation at the specified study intervals and undergo follow-up requirements.
- The patient or legal representative has provided written informed consent using a form that is reviewed and approved by the EC for the Clinical Site.
Pre-Intervention
- Target lesion has ≥ 50% stenosis as demonstrated angiographically.
- Lesion length ≤ 15 cm.
- Reference vessel diameter of 5 to 6 mm.
- Patient has at least 1 vessel run-off prior to treatment.
Exclusion Criteria:
Screening
- The subject is pregnant or will become pregnant during the study or has any other condition that would preclude having x-rays. (Pre-menopausal women must have a negative pregnancy test within 7 days of the procedure.)
- Patients who have experienced a cardiovascular accident (CVA) or a myocardial infarction (MI) within 3 months prior to the procedure.
- Subject has had or plans to have a surgical or interventional procedure within 30 days before or after the implantation procedure of the SAMBA Stent.
- Existing hemorrhagic disease or coagulation problems or inability to take dual anti-platelet therapy.
- Contrast allergy that cannot be corrected with medication (e.g. steroids, etc.).
- Subject has other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment and the procedures and evaluations pre- and post-treatment.
- Patient is currently participating in another investigational drug or device study.
Pre-Intervention
- Uncorrectable severe aorto-iliac occlusive disease or severe common femoral artery stenosis preventing access or limiting inflow (e.g., stenosis greater than 50%).
- Uncorrectable occlusive disease limiting outflow (e.g., stenosis greater than 50%)
- Patients with previous surgery in the target vessel or stent that will be closer than 2 cm to either edge of SAMBA Stent(s).
- Lack of 1 cm of healthy vessel proximal to proximal target
- Lack of popliteal reconstitution (at least 2 cm of normal distal popliteal).
- Inability to cross the lesion with a guidewire.
- More than 1 lesion in the same limb requiring treatment that will not be covered by continuous stenting.
- Unsuccessful balloon pre-dilation (i.e., the residual stenosis is greater than 30%).
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Stent placement
|
Stenting of atherosclerotic lesions post pre-dilatation of lesion(s)
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
The primary safety endpoint is defined as freedom from all cause death, unplanned index limb amputation, and target lesion revascularization.
Tidsramme: through 30 days
|
through 30 days
|
|
The primary efficacy endpoint is defined as stent patency via Color Duplex Ultrasound (Peak Velocity Ratio ≤ 2.5).
Tidsramme: 3 months
|
3 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Clinically-Driven Target Lesion Revascularization (i.e., with documented preintervention evidence of at least 50% diameter stenosis (quantitative angiographic ≥ 50% or PSVR > 2.5).
Tidsramme: 12 months
|
12 months
|
|
Change in Rutherford Classification compared to pre-implant.
Tidsramme: 12 months
|
12 months
|
|
Stent Patency via Color Duplex Ultrasound (Peak Systolic Velocity Ratio ≤ 2.5).
Tidsramme: 12 months
|
12 months
|
|
Stent Fractures.
Tidsramme: 12 months
|
12 months
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Dierk Scheinert, MD, Herz-Zentrum Leipzig
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. april 2009
Primær færdiggørelse (Forventet)
1. september 2010
Studieafslutning (Forventet)
1. september 2010
Datoer for studieregistrering
Først indsendt
4. juni 2010
Først indsendt, der opfyldte QC-kriterier
7. juni 2010
Først opslået (Skøn)
8. juni 2010
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
8. juni 2010
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
7. juni 2010
Sidst verificeret
1. juni 2010
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 60-00857-01
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .